CytomX Therapeutics, Inc. stock is up 20% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November.
CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.